Brown J - Search Results

1

Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.

James ND, Pirrie SJ, Pope AM, Barton D, Andronis L, Goranitis I, Collins S, Daunton A, McLaren D, O'Sullivan J, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown J, Chakraborti P, Hussain S, Russell M, Billingham LJ. James ND, et al. Among authors: brown j. JAMA Oncol. 2016 Apr;2(4):493-9. doi: 10.1001/jamaoncol.2015.5570. JAMA Oncol. 2016. PMID: 26794729 Free article. Clinical Trial.

2

The role of bisphosphonates in breast and prostate cancers.

Brown JE, Neville-Webbe H, Coleman RE. Brown JE, et al. Endocr Relat Cancer. 2004 Jun;11(2):207-24. doi: 10.1677/erc.0.0110207. Endocr Relat Cancer. 2004. PMID: 15163299 Review.

3

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.

Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R. Coleman RE, et al. Among authors: brown je. J Clin Oncol. 2005 Aug 1;23(22):4925-35. doi: 10.1200/JCO.2005.06.091. Epub 2005 Jun 27. J Clin Oncol. 2005. PMID: 15983391

4

Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid.

Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, Purohit OP, McCloskey E, Coleman RE. Brown JE, et al. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5406-10. doi: 10.1158/1078-0432.CCR-07-0247. Clin Cancer Res. 2007. PMID: 17875770 Clinical Trial.

5

Osteoporosis and antiandrogens. An under-recognised risk.

Sherriff JM, Brown JE, James ND. Sherriff JM, et al. BMJ. 2010 Jan 13;340:c143. doi: 10.1136/bmj.c143. BMJ. 2010. PMID: 20071430 No abstract available.

6

Osteoporosis in patients with prostate cancer on long-term androgen deprivation therapy: an increasing, but under-recognized problem.

Brown JE, Sherriff JM, James ND. Brown JE, et al. BJU Int. 2010 Apr;105(8):1042-3. doi: 10.1111/j.1464-410X.2010.09251.x. Epub 2010 Mar 1. BJU Int. 2010. PMID: 20201833 No abstract available.

7

Prognostic factors for skeletal complications from metastatic bone disease in breast cancer.

Brown JE, Cook RJ, Lipton A, Costa L, Coleman RE. Brown JE, et al. Breast Cancer Res Treat. 2010 Oct;123(3):767-79. doi: 10.1007/s10549-010-0981-1. Epub 2010 Jun 24. Breast Cancer Res Treat. 2010. PMID: 20574672

8

Skeletal complications and survival in renal cancer patients with bone metastases.

Woodward E, Jagdev S, McParland L, Clark K, Gregory W, Newsham A, Rogerson S, Hayward K, Selby P, Brown J. Woodward E, et al. Among authors: brown j. Bone. 2011 Jan;48(1):160-6. doi: 10.1016/j.bone.2010.09.008. Epub 2010 Sep 18. Bone. 2011. PMID: 20854942

9

Zoledronic acid.

Coleman R, Burkinshaw R, Winter M, Neville-Webbe H, Lester J, Woodward E, Brown J. Coleman R, et al. Among authors: brown j. Expert Opin Drug Saf. 2011 Jan;10(1):133-45. doi: 10.1517/14740338.2011.540387. Epub 2010 Nov 29. Expert Opin Drug Saf. 2011. PMID: 21114419 Review.

10

Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).

Rathbone EJ, Brown JE, Marshall HC, Collinson M, Liversedge V, Murden GA, Cameron D, Bell R, Spensley S, Agrawal R, Jyothirmayi R, Chakraborti P, Yuille F, Coleman RE. Rathbone EJ, et al. Among authors: brown je. J Clin Oncol. 2013 Jul 20;31(21):2685-91. doi: 10.1200/JCO.2012.46.4792. Epub 2013 Jun 24. J Clin Oncol. 2013. PMID: 23796998 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21,197 results

Search Page

Filters